• Home
  • Study Details
Coming Soon

A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer

The goal of this research study is to test a new study treatment for a specific type of stomach cancer. It is focused on people whose tumors are CLDN18.2 positive, PD-L1 positive, and HER2 negative. This new study treatment has 3 parts: 1. A study drug called zolbetuximab 2. Another study drug called pembrolizumab 3. Standard chemotherapy (mFOLFOX or CAPOX) Researchers want to know if this combination is safe and if it works better than current treatments for people living with this specific type of stomach cancer

Age & Gender

  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Ashwin Somasundaram
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Colorectal)

IRB Number

25-0880

ClinicalTrials.gov

NCT06901531

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research